Notably, a high population (76.9) of IL-17A+ T-cells (CD3+, CD45+; Fig. 4G) was detected in NMO rats without the treatment, but this population was lower (17.7) following the anti-RGMa mAb treatment (Fig. 4H). The gene discussed is IL17A; the disease is neuromyelitis optica.